The Renin-Angiotensin System in Essential Hypertension

  • Tell a FriendPrint

Although ACE Inhibitors and Angiotensin Receptor Blockers are effective blood pressure lowering agents, the exact mechanisms by which these agents lower BP are still not fully understood. This study aims to compare the blood pressure and hormonal responses (plasma renin activity and aldosterone) to the ACE inhibitor enalapril and ARB candesartan in individuals with mild essential hypertension...

Brief Summary

Official Title: “The Renin-Angiotensin System in Essential Hypertension”

Although ACE Inhibitors and Angiotensin Receptor Blockers are effective blood pressure lowering agents, the exact mechanisms by which these agents lower BP are still not fully understood. This study aims to compare the blood pressure and hormonal responses (plasma renin activity and aldosterone) to the ACE inhibitor enalapril and ARB candesartan in individuals with mild essential hypertension.

  • Study Type: Interventional
  • Study Design: Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label

Intervention(s) in this Clinical Trial

  • Drug: Enalapril 20 mg bd
  • Drug: Candesartan 8 mg bd

Outcome Measures for this Clinical Trial

Primary Measures

  • Change in BP
  • Change in PRA and aldosterone

Criteria for Participation in this Clinical Trial

Inclusion Criteria:

  • Essential Hypertension
  • SBP 140-159 mmHg
  • DBP 90-99 mmHg

Exclusion Criteria:

  • Intolerance of or allergy to ACE Inhibitors or ARBS
  • Pregnant or Breastfeeding
  • Pre-menopausal women
  • Uncontrolled cardiac or renal failure
  • Diabetes mellitus

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: 70 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Clinical Trial Investigator Information

Lead Investigator: St George's, University of London Other

Overall Clinical Trial Officials and Contacts

Timothy WR Doulton, BSc MRCP Principal Investigator SGUL  

Overall Contact: Timothy WR Doulton, BSc MRCP +44 208 725 3176 tdoulton@sgul.ac.uk

Additional Information

Information obtained from ClinicalTrials.gov on February 12, 2012

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00141583

Study ID Number: LREC 01.87.10

ClinicalTrials.gov Identifier: NCT00141583

Health Authority: United Kingdom: Research Ethics Committee

  • Tell a FriendPrint

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00141583